Clinical trial
Multi-country Real-World Observational Study of MIrvetuximab Soravtansine in Treating Platinum-REsistant FRALphA Positive Ovarian, Fallopian Tube, and Peritoneal Cancer- MIRELA
NCT07896421 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-country Real-World Observational Study of MIrvetuximab Soravtansine in Treating Platinum-REsistant FRALphA Positive Ovarian, Fallopian Tube, and Peritoneal Cancer- MIRELA
- Lead sponsor
- AbbVie
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- October 21, 2026
- Completion date
- April 30, 2030
- Enrollment
- 500 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
platinum-resistant frα-positive fallopian tube cancer, platinum-resistant frα-positive ovarian cancer, platinum-resistant frα-positive peritoneal cancer
Arms
As registered; 1 arm.
-
Mirvetuximab Soravtansine (MIRV)
Participants with FRα positive platinum-resistant ovarian, primary peritoneal or fallopian tube cancer and are scheduled to receive treatment with MIRV in accordance with the local label of the participating country.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Treatment Duration of MIRV Among Participants With Platinum-Resistant FRα-Positive Ovarian Cancer
Treatment duration of MIRV is defined as (the maximum end date of MIRV dosing date - the minimum start date of MIRV +21).
Lead sponsor's other trials
AbbVie, most recent start first.
+1,194 more trials See the organization page
Similar trials
Same condition (Fallopian Tube Neoplasms) and phase, most recent start first.
+77 more trials See the condition page